Who We Are

OHF is a partner, an alliance and a movement. We bring together people living with hyperoxaluria, families, care partners,  scientists, doctors, advocates, donors and volunteers to join forces to improve lives and advance towards a cure. 

Since 1989, we’ve made tangible progress on all fronts, providing hope, energizing science to help save lives. Today, we continue to: 

  • Partner with the scientific community to fund game-changing research that provides better outcomes  
  • Include the patient voice every step of the way  
  • Convene the best minds from around the world to find new approaches that enhance care and move us closer to a cure 

We will not stop until a cure is found.

Our Team

We’re led by a team of passionate people who strive to empower the Hyperoxaluria community. Get to know us.

Kim Hollander

Executive Director
New York, New York

Julie Bertarelli

Operations Coordinator
St. Louis, Missouri

Board of Directors

Our voluntary Board of Directors provides oversight and governance. Directors represent a variety of professional backgrounds with one thing in common: They all have been touched by hyperoxaluria and its complications.

William C. Tidmore, Jr. MD

President
Valdosta, Georgia

Tim Berra

Vice President
St. Louis, Missouri

Brett Rosen

Chair / Treasurer
New York, New York

Debra Wattenberg MD

VP of Science & Medical Affairs
New York, New York

Art McGill

Director
Aliso Viejo, CA

Brendan McGovern

Director
New Hyde Park, New York

Scientific Advisory Board and Council 

The Scientific Advisory Board and Scientific Advisory Council are rotating committees of thought leaders who act as external advisors. They provide guidance and direction on our overall research strategy.

Meet the

Scientific Advisory Board

View Members

Meet the

Scientific Advisory Council

View Members

Corporate Alliance

We are a global community paving the way for change.  Partner with us. Together, we can empower, connect and inspire the Hyperoxaluria community.

Alnylam
arbor-biotech-logo-WEB

Financial Statements